A Mixed Bag | GenomeWeb

A Mixed Bag

Times are still difficult for many biotechs, but Ed Silverman writes at Pharmalot that the situation is actually a bit variable. Drawing on a report from consulting firm BDO, Silverman notes that biotech firms spent slightly more on R&D in 2011 than in 2010, though he adds that while large biotechs reported about 33 percent increase in revenue, smaller biotechs have not seen such large gains, reporting 12 percent decline in revenue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.